Observational studyPediatric pulmonology2026
Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two-Season Analysis.
Observational study in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesNirsevimab was approved in Europe in 2022 for respiratory syncytial virus (RSV) prevention. In October 2023, Catalonia (Spain) launched a universal immunization program for infants under 6 months during their first RSV season. This study aims to assess the characteristics of patients admitted with bronchiolitis following nirsevimab implementation and to compare the features of the immunized patients across two consecutive seasons.
methodsThis prospective, observational, single-center study included infants aged up to 12 months admitted for bronchiolitis between October 2023 and May 2025, comparing clinical and epidemiological data across two seasons (S1: October 2023-May 2024; S2: October 2024-May 2025).
results574 patients were included (S1: 352; S2: 222), with a median age of 3.2 months (interquartile range [IQR]: 1.5-6.5). Most were previously healthy (437/574, 76.1%) and immunized with nirsevimab (406/574, 70.7%). RSV was detected in 215/574 (37.5%) of cases. 159/574 (27.7%) required Pediatric Intensive Care Unit (PICU) admission, and the median length of hospital stay was 5 days (IQR:3-8). In S2, immunization rates increased (S1:61.6% vs S2:85.1%, p = < 0.001) whereas RSV infections decreased (S1:41.2% vs S2: 31.5%, p = 0.020). Among immunized patients, S2 exhibited a higher proportion of healthy children (S1:65.0% vs S2:77.8%, p = 0.005), fewer PICU admissions (S1:33.2% vs S2:21.2%, p = 0.007) and shorter hospital stays (S1: 6 [IQR:4-9.5] days vs S2: 5 [IQR:3-7.5] days, p = 0.033). Furthermore, in multivariable logistic regression analysis, admission during the second season remained independently associated with a lower risk of PICU admission (adjusted OR 0.587, 95% CI 0.368-0.936; p = 0.025).
conclusionAmong hospitalized infants with bronchiolitis after nirsevimab implementation, immunized patients admitted during the second season showed more favorable clinical outcomes, including lower PICU utilization and shorter hospitalizations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.